BonVie+™ (EP Granules with Tobramycin)
Periprosthetic Joint Infection (PJI) in two-stage revision surgery
Phase 2/3Active
Key Facts
Indication
Periprosthetic Joint Infection (PJI) in two-stage revision surgery
Phase
Phase 2/3
Status
Active
Company
About Elute, Inc
Elute, Inc., founded in 2018 and based in Cambridge, USA, is an emerging private company pioneering a novel drug-eluting platform for orthopedic applications. Its core technology involves polymer-controlled release of therapeutics from implantable materials, with its lead program, BonVie+™, in a pivotal Phase 2/3 clinical trial (MAGIC) for treating periprosthetic joint infections (PJI). The company is led by a team of technical and clinical experts, including co-founders with deep expertise in biomaterials science, and is positioned to address a large, costly, and growing market for bone graft substitutes and infection prevention in orthopedic surgery.
View full company profile